Glaucoma, the leading cause of blindness, is often marked by loss of retinal ganglion cells (RGCs). Necroptosis, a form of programmed cell death, plays a critical role in RGC death, mediated by receptor-interacting protein kinase 3 (RIPK3). A team of scientists from China leveraged advanced artificial intelligence (AI) technologies to identify RIPK3 inhibitors, including the compound HG9-91-01, which demonstrated neuroprotective effects. This AI-driven approach holds promise for developing novel therapeutic strategies for acute glaucoma.

CAMBRIDGE, Mass., January 2, 2025 — Insilico Medicine (‘Insilico’), a clinical-stage generative artificial intelligence (AI)-driven drug discovery and development company, today announced the nomination of ISM1745, a potentially best-in-class MTA cooperative PRMT5 inhibitor with AI-powered novel scaffold, as preclinical candidate (PCC) for the treatment of MTAP-deleted cancers. Based on de novo design results of Chemistry42, ISM1745 marks the fifth PCC nomination achieved by the Insilico team in the year of 2024, bringing the total number since 2021 to 22.

A new study underscores the value of physical activity. Researchers found patients who responded in a survey that they are physically active have a statistically significant lower risk of having 19 chronic conditions. Results appear in Preventing Chronic Disease, from the U.S. Centers for Disease Control and Prevention.

Highly pathogenic H5N1 avian influenza A virus (HPAI H5N1) remains a low risk to the general public, and public health experts in the United States believe that available treatments and vaccines, as well as those in development, are sufficient to prevent severe disease. However, the National Institutes of Health (NIH) and its federal partners remain focused on monitoring the virus and evaluating changes, according to leading officials at the National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH. 

Researchers have developed a biomimetic artificial muscle that replicates the structure and mechanical properties of natural muscle tissue, offering a promising solution for volumetric muscle loss treatment. Published in National Science Review, the study highlights the material's superior biocompatibility, mechanical adaptability, and multifunctionality. The artificial muscle promotes myogenic differentiation, enhances angiogenesis, and demonstrates exceptional actuation performance, making it a viable candidate for applications in prosthetics and regenerative medicine. This innovation sets the stage for new directions in clinical treatments and advanced biomedical materials.